switching from semaglutide to tirzepatide dose dosage chart Switching from Semaglutide to Tirzapetide

Results Participants Among the 335 participants from the modified intent-to-treat population who were randomized to the placebo arm in the SURMOUNT-4 study, 308 participants (with any weight measurement after week 36) achieved at least 10% reduction in imputed weight by the end of the 36-week open-label lead-in period with tirzepatide treatment and were included in this analysis (eFigure 1 in Supplement 2)

Due to persistent symptoms and concern for appendicitis, a computed tomography (CT) of the abdomen and pelvis with contrast was obtained (Figure 1)

What the clinical trials actually show The SURMOUNT-1 trial remains the landmark study for tirzepatide and weight loss

In Type 1 diabetes, the pancreas is not capable of releasing insulin anymore

Some individuals have contraindications to incretin-based medications, such as clinically significant gastroparesis or history of pancreatitis

GLP-1s (glucagon-like peptide-1 receptor agonists), also known as incretin mimetics, are a class of prescription medications that have been proven to be effective in the treatment of type 2 diabetes and in support of weight loss